About S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1
S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1 (TYW1) is a protein
from Homo sapiens identified by UniProt accession
Q9NV66, 732 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
Disease associations (25)
Diseases linked to this target (Open Targets).
- protein measurement · score 0.10
- body weight · score 0.07
- hemoglobin E-beta-thalassemia syndrome · score 0.05
- hemoglobin D disease · score 0.04
- DNA methylation · score 0.04
- Hemolytic anemia due to red cell pyruvate kinase deficiency · score 0.04
- hemoglobin E disease · score 0.03
- dominant beta-thalassemia · score 0.03
- gait measurement · score 0.03
- congenital dyserythropoietic anemia type 4 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Experimental structures are not indexed in MolForge yet —
search RCSB PDB for Q9NV66.
Amino-acid sequence (732 residues)
MDPSADTWDL FSPLISLWIN RFYIYLGFAV SISLWICVQI VIKTQGKNLQ EKSVPKAAQD LMTNGYVSLQ EKDIFVSGVK IFYGSQTGTA KGFATVLAEA VTSLDLPVAI INLKEYDPDD HLIEEVTSKN VCVFLVATYT DGLPTESAEW FCKWLEEASI DFRFGKTYLK GMRYAVFGLG NSAYASHFNK VGKNVDKWLW MLGAHRVMSR GEGDCDVVKS KHGSIEADFR AWKTKFISQL QALQKGERKK SCGGHCKKGK CESHQHGSEE REEGSHEQDE LHHRDTEEEE PFESSSEEEF GGEDHQSLNS IVDVEDLGKI MDHVKKEKRE KEQQEEKSGL FRNMGRNEDG ERRAMITPAL REALTKQGYQ LIGSHSGVKL CRWTKSMLRG RGGCYKHTFY GIESHRCMET TPSLACANKC VFCWRHHTNP VGTEWRWKMD QPEMILKEAI ENHQNMIKQF KGVPGVKAER FEEGMTVKHC ALSLVGEPIM YPEINRFLKL LHQCKISSFL VTNAQFPAEI RNLEPVTQLY VSVDASTKDS LKKIDRPLFK DFWQRFLDSL KALAVKQQRT VYRLTLVKAW NVDELQAYAQ LVSLGNPDFI EVKGVTYCGE SSASSLTMAH VPWHEEVVQF VHELVDLIPE YEIACEHEHS NCLLIAHRKF KIGGEWWTWI DYNRFQELIQ EYEDSGGSKT FSAKDYMART PHWALFGASE RGFDPKDTRH QRKNKSKAIS GC
Explore S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets